A. E. Eskazan And D. Ozmen, "Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?," EXPERT REVIEW OF HEMATOLOGY , vol.10, no.7, pp.583-586, 2017
Eskazan, A. E. And Ozmen, D. 2017. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?. EXPERT REVIEW OF HEMATOLOGY , vol.10, no.7 , 583-586.
Eskazan, A. E., & Ozmen, D., (2017). Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?. EXPERT REVIEW OF HEMATOLOGY , vol.10, no.7, 583-586.
Eskazan, Ahmet, And Deniz Ozmen. "Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?," EXPERT REVIEW OF HEMATOLOGY , vol.10, no.7, 583-586, 2017
Eskazan, Ahmet E. And Ozmen, Deniz. "Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?." EXPERT REVIEW OF HEMATOLOGY , vol.10, no.7, pp.583-586, 2017
Eskazan, A. E. And Ozmen, D. (2017) . "Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?." EXPERT REVIEW OF HEMATOLOGY , vol.10, no.7, pp.583-586.
@article{article, author={Ahmet Emre EŞKAZAN And author={Deniz Ozmen}, title={Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?}, journal={EXPERT REVIEW OF HEMATOLOGY}, year=2017, pages={583-586} }